Review of IgG4-related Hashimoto Thyroiditis With Best Practice Recommendations for Diagnosis and Reporting.


Journal

Advances in anatomic pathology
ISSN: 1533-4031
Titre abrégé: Adv Anat Pathol
Pays: United States
ID NLM: 9435676

Informations de publication

Date de publication:
01 Mar 2022
Historique:
pubmed: 18 10 2021
medline: 11 2 2022
entrez: 17 10 2021
Statut: ppublish

Résumé

Found in virtually any organ system, immunoglobulin (Ig) G4-related disease (RD) is a recently recognized immune-mediated, systemic, a fibroinflammatory disease characterized histologically by storiform fibrosis, obliterative phlebitis, and lymphoplasmacytic infiltrate with IgG4-positive plasma cells (PCs). IgG4-related Hashimoto thyroiditis (IgG4-RHT), also called IgG4-related thyroiditis, shares many features with IgG4-RD but is distinct in several ways. A case of IgG4-RHT in a 51-year-old African American female is assembled together with a literature review which uncovered 82 cases of IgG4-RHT. The findings and criteria which the respective authors used to reach their diagnoses are analyzed. Findings common to all studies are lymphoplasmacytic infiltration and IgG4-positive staining, while most describe follicular atrophy (95.2%, 79/83). Stromal fibrosis involving >33% of thyroid architecture was reported in 74% (58/78) of cases. While few reports observed storiform fibrosis, all describe lack of obliterative phlebitis or systemic involvement. Discrepancies between reports exist in immunostaining thresholds, as well as grading systems for stromal fibrosis. Based on our review of the literature and experience, we propose a set of best practice recommendations for the diagnosis of IgG4-RHT. Our diagnostic criteria are (1) lack of extrathyroidal IgG4-RD, (2) the fibroinflammatory process should not extend beyond the thyroid capsule, (3) stromal fibrosis comprises at least 30% of the involved tissue, (4) >30% IgG4/IgG ratio, with absolute immunostaining cutoffs varying by the degree of stromal fibrosis: for >50% stromal fibrosis use >20 IgG4+PCs/HPF, for 30% to 50% fibrosis use >30 IgG4+PCs/HPF, (5) fibrosis infiltrates the interlobular/interfollicular space, (6) features of follicle injury, and (7) obliterative phlebitis is not required.

Identifiants

pubmed: 34657097
doi: 10.1097/PAP.0000000000000324
pii: 00125480-202203000-00003
doi:

Substances chimiques

Immunoglobulin G 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-107

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors have no funding or conflicts of interest to disclose.

Références

Li Y, Zhou G, Ozaki T, et al. Distinct histopathological features of Hashimoto’s thyroiditis with respect to IgG4-related disease. Mod Pathol. 2012;25:1086–1097.
Deshpande V. IgG4 related disease of the head and neck. Head Neck Pathol. 2015;9:24–31.
Stone JH, Khosroshahi A, Deshpande V, et al. IgG4-related disease: recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64:3061–3067.
Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366:539–551.
Deshpande V, Zen Y, Chan JKC, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–1192.
Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease. Lancet. 2015;385:1460–1471.
Kakudo K, Li Y, Taniguchi E, et al. IgG4-related disease of the thyroid glands. Endocr J. 2012;59:273–281.
Rotondi M, Carbone A, Coperchini F, et al. Diagnosis of endocrine disease: IgG4-related thyroid autoimmune disease. Eur J Endocrinol. 2019;180:R175–R183.
Li Y, Inomata K, Nishihara E, et al. IgG4 thyroiditis in the Asian population. Gland Surg. 2020;9:1838–1846.
Li Y, Bai Y, Liu Z, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto’s autoimmune thyroiditis. Pathol Int. 2009;59:636–641.
Zhang J, Zhao L, Gaeo Y, et al. A classification of Hashimoto’s thyroiditis based on immunohistochemistry for IgG4 and IgG. Thyroid. 2014;24:364–370.
Raess PW, Habashi A, El Rassi E, et al. Overlapping morphologic and immunohistochemical features of Hashimoto thyroiditis and IgG4-related thyroid disease. Endocr Pathol. 2015;26:170–177.
Jokisch F, Kleinlein I, Haller B, et al. A small subgroup of Hashimoto’s thyroiditis is associated with IgG4-related disease. Virchows Arch. 2016;468:321–327.
Luiz HV, Gonçalves D, da Silva TN, et al. IgG4-related Hashimoto’s thyroiditis—a new variant of a well known disease. Arq Bras Endocrinol Metabol. 2014;58:862–868.
Abo Salook M, Benbassat C, Strenov Y, et al. IgG4-related thyroiditis: a case report and review of literature. Endocrinol Diabetes Metab Case Rep. 2014;2014:140037.
Kang SY, Kim YN, Kim SK, et al. IgG4-related Hashimoto’s thyroiditis of the thyroid gland. Int Surg. 2017;102:222–226.
Sakai Y, Imamura Y. Case report: IgG4-related mass-forming thyroiditis accompanied by regional lymphadenopathy. Diagn Pathol. 2018;13:3.
Zhao Z, Lee YJ, Zheng S, et al. IgG4-related disease of the thyroid gland requiring emergent total thyroidectomy: a case report. Head Neck Pathol. 2019;13:523–527.
Li Y, Nishihara E, Hirokawa M, et al. Distinct clinical, serological, and sonographic characteristics of Hashimoto’s thyroiditis based with and without IgG4-positive plasma cells. J Clin Endocrinol Metab. 2010;95:1309–1317.
Katz SM, Vickery AL. The fibrous variant of Hashimoto’s thyroiditis. Hum Pathol. 1974;5:161–170.
Deshpande V, Huck A, Ooi E, et al. Fibrosing variant of Hashimoto thyroiditis is an IgG4 related disease. J Clin Pathol. 2012;65:725–728.

Auteurs

Steven H Adams (SH)

College of Medicine.
Department of Pathology, Stony Brook University Hospital, Stony Brook, NY.

Lorenzo Gitto (L)

Department of Pathology, SUNY Upstate Medical University, Syracuse.

Serenella Serinelli (S)

Department of Pathology, SUNY Upstate Medical University, Syracuse.

Christopher Curtiss (C)

Department of Pathology, SUNY Upstate Medical University, Syracuse.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH